Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,220.10 -74.38 -0.49%
S&P 500 1,638.01 -12.50 -0.76%
Nasdaq 3,436.85 -22.57 -0.65%
Ticker Volume Price Price Delta
STOXX 50 2,754.47 -22.31 -0.80%
FTSE 100 6,648.45 -48.34 -0.72%
DAX 8,271.68 -80.30 -0.96%
Ticker Volume Price Price Delta
Nikkei 14,612.50 +128.47 0.89%
Hang Seng 22,618.70 -51.01 -0.23%
S&P/ASX 200 4,983.50 -78.95 -1.56%
  • Exchange: NASDAQ GS
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

Halozyme Therapeutics Inc

+ Add to Watchlist

HALO:US

7.3900 USD 0.0600 0.81%

As of 10:16:40 ET on 05/24/2013.

Company Profile for Halozyme Therapeutics Inc (HALO)

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.

Contact Information

Halozyme Therapeutics Inc

11388 Sorrento Valley Road
San Diego, CA 92121
United States
Phone: 1-858-794-8889
Fax: 1-858-259-2539

Key Executives for Halozyme Therapeutics Inc (HALO)

Gregory Ian Frost "Greg"President/CEO/Co-FounderDavid A RamsayChief Financial Officer
James P ShafferVP/Chief Commercial OfficerH Michael Shepard "Mike"VP/Chief Scientific Officer
Jean I LiuVP/Secretary/General Counsel

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil